Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

Introduction to the Search&Match methodology Dry search rather than classical laboratory research We developed a Search&Match process focusing on analysis of immunomodulating substances naturally occurring in the human body, in order to identify promising candidates for the development of medicinal products specifically targeted to the treatment of rare diseases 8
Introduction to the Search&Match methodology Search 31000 journals and 50million publications Search algorithms that: • Access privileged qualified data sources for collecting all knowledge on human peptides and rare diseases • Elaborate all relevant information • Populate our database to feed the bio-mathematical model for the Match Search Physical Records Libraries of Periodicals & Textbooks Electronic Records Publications in Multiple Languages Academia Diagrams & Images Lab Results Peptide Match 312 peptides with 7000 rare diseases Match algorithms that: • Apply our bio-mathematical model to link the gathered information on peptides, physiological pathways and resulting biological activities with the patho-physiological signs & symptoms of rare diseases • Create multiple peptide-disease matches generating the best possible medicinal platforms candidates Match Disease Therapies MPC 9
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3 and 4: mondoBIOTECH at a glance • Headqu
Page 5 and 6: Board of Directors Robert Edward Pa
Page 7: Our approach to drug discovery •
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29 and 30: Intellectual Property Strategy & Cu
Page 31 and 32: mondoBIOTECH’s IP Strategy Two in
Page 33 and 34: mondoBIOTECH’s IP Strategy: Two I
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 40 and 41: Diversifying the Risk in Drug Disco
Page 42 and 43: Current Pipeline DasKloster 1000-01
Page 46: Scientific Snapshot Information: DK
Page 49 and 50: Scientific Snapshot Information: DK
Page 51 and 52: Products licensed DasKloster 1001-0
Page 53 and 54: Licensed Products • Aviptadil pla
Page 55: mondoBIOTECH holding AG DasKloster

Mondobiotech Holding AG Company presentation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?